Immutep Limited logo
Immutep Limited IMMP
$ 3.04 3.05%

Annual report 2025
added 01-03-2026

report update icon

Immutep Limited Balance Sheet 2011-2026 | IMMP

Annual Balance Sheet Immutep Limited

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- -17.4 M -8.93 M -16.8 M -6.46 M -15.9 M -5.25 M -14.2 M -22 M -17 M -45.9 M

Long Term Debt

- - - - - 8.79 M 7.64 M 6.65 M 5.78 M 5.03 M - - - - -

Long Term Debt Current

205 K 234 K 185 K 173 K 208 K 129 K - - - - - - - - -

Total Non Current Liabilities

- - - - - - 10.9 M 9.62 M 5.8 M 5.76 M 1.91 M 14.8 K 5.75 K 10.3 K 4.44 K

Total Liabilities

13.3 M 12.1 M 11 M 8.09 M 8.76 M 13.3 M 16.2 M 13.5 M 8.43 M 7.24 M 6.29 M 2.79 M 3.57 M 4.45 M 2.54 M

Deferred Revenue

- - - - - 1.29 M - - - - - - - - -

Retained Earnings

- - - - - -276 M -262 M -245 M -232 M -222 M -160 M -128 M -115 M -99.7 M -79.8 M

Total Assets

157 M 202 M 147 M 102 M 82 M 46.6 M 40.5 M 47 M 35 M 42.6 M 31 M 25.4 M 32.8 M 41.6 M 57.6 M

Cash and Cash Equivalents

67.4 M 162 M 123 M 80 M 60.6 M 26.3 M 16.6 M 23.5 M 12.2 M 20.9 M - - - - -

Book Value

144 M 190 M 136 M 94.1 M 73.3 M 33.3 M 24.4 M 33.5 M 26.5 M 35.3 M 24.7 M 22.6 M 29.2 M 37.2 M 55.1 M

Total Shareholders Equity

- - - - - 33.3 M 24.4 M 33.5 M 26.5 M 35.3 M - - - - -

All numbers in AUD currency

Quarterly Balance Sheet Immutep Limited

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - - - 80.1 K - - - 133 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - 3.42 M - - - 9.93 M - - - 10.9 M - - - 9.62 M - - - 5.8 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - - - 8.76 M - - - 13.3 M - - - 16.2 M - - - 13.5 M - - - 8.43 M - - - 7.24 M - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - - - -275 M - - - -276 M - - - -262 M - - - -245 M - - - -232 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - - - 82 M - - - 46.6 M - - - 40.5 M - - - 47 M - - - 35 M - - - 42.6 M - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - - - 60.6 M - - - 26.3 M - - - 16.6 M - - - 23.5 M - - - 12.2 M - - - 20.9 M - - - 6.76 M - - - - - - - - - - - - - - - - -

Book Value

- - - - - - 73.3 M - - - 33.3 M - - - 24.4 M - - - 33.5 M - - - 26.5 M - - - 35.3 M - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - - - 73.3 M - - - 33.3 M - - - 24.4 M - - - 33.5 M - - - 26.5 M - - - 35.3 M - - - 24.7 M - - - - - - - - - - - - - - - - -

All numbers in AUD currency

Balance Sheet is a fundamental financial report of Immutep Limited, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adagene Adagene
ADAG
$ 1.7 11.11 % $ 95.7 M chinaChina
AstraZeneca PLC AstraZeneca PLC
AZN
$ 95.05 0.42 % $ 96.9 B britainBritain
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.6 -11.64 % $ 408 M britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.53 0.14 % $ 8.49 B australiaAustralia
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Biogen Biogen
BIIB
$ 183.04 -2.44 % $ 26.7 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
BioNTech SE BioNTech SE
BNTX
$ 100.16 0.31 % $ 27.2 B germanyGermany
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.1 -0.97 % $ 8.92 B israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 205.63 1.3 % $ 5 B danmarkDanmark
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 37.6 0.25 % $ 3.88 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 22.6 -0.53 % $ 2.68 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 55.0 3.28 % $ 4.44 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 54.77 1.73 % $ 4.62 B schweizSchweiz
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 10.78 -0.14 % $ 710 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 60.85 -2.66 % $ 6.81 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 17.69 4.0 % $ 1.72 B franceFrance
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 25.84 -5.62 % $ 1.66 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 4.2 -4.76 % $ 116 M franceFrance
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
$ 12.63 -3.66 % $ 269 K usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 29.04 4.69 % $ 1.41 B usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 1.1 -1.0 % $ 27.9 M israelIsrael
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.59 1.43 % $ 1.55 B britainBritain
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 5.87 13.76 % $ 322 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 63.42 -1.77 % $ 8.48 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
$ 14.29 0.04 % $ 4.35 B usaUSA